My guess is that the reason for the trial size reduction is because it is a P2 trial. Therefore, they want to figure out the right endpoints and get it done asap and for as little cost as possible. They expect that the FDA would not consider approving the indication for a P2. So, they are trying to get it done and move on to the registrational P3.